Physician profile
Michael D Harris
NPI 1942212279
$777.42
in general payments reported to CMS, 2019-2025
12 companies · $33.99 in 2025
The $33.99 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $279 · 2020: $13.33 · 2021: $178 · 2022: $46.91 · 2023: $89.29 · 2024: $137 · 2025: $33.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $225 · Education: $35.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $224.94 |
| Education | $35.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $286.63 | 2019-2024 | Omnipod |
| Novo Nordisk INC | $96.82 | 2024-2025 | Rybelsus, Ozempic |
| Dexcom, INC. | $89.59 | 2019 | |
| Sanofi-Aventis U.S. LLC | $87.00 | 2021 | |
| Lilly USA, LLC | $64.66 | 2022-2023 | Mounjaro, Trulicity |
| Corcept Therapeutics | $56.76 | 2023-2024 | Korlym |
| Tandem Diabetes Care, INC. | $20.52 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Amgen INC. | $17.99 | 2019 | |
| Kvk-Tech, INC. | $17.57 | 2019 | |
| Ibsa Pharma INC. | $14.58 | 2023 | Tirosint, Licart |
| Medtronic, INC. | $14.30 | 2022 | |
| Senseonics, Incorporated | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.